Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

By R. Nahta, Dihua Yu, M. Hung, G. Hortobagyi, F. Esteva. Nature Clinical Practice Oncology, 2006

902 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/d75ed93ef60439d5d8ee56b817f665d8cf79b448

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Sliwkowski
2. M. Lacouture

In Radiology, Nuclear Medicine and Imaging

1. M. Sliwkowski
2. Paul Polakis
3. M. Lacouture

Citations in the corpus

• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “Despite these diverse mechanisms of action, a significant proportion of patients treated with trastuzumab either do not respond initially or relapse after experiencing a period of clinical response (5, 9).”
• Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, background): “HER2 is overexpressed in approximately 25 % of invasive breast cancer (Nahta et al. 2006), but it is minimally expressed by normal adult tissues (Press et al.”